Last reviewed · How we verify
Juvenile psoriatic arthritis
Approved treatments
- Tasocitinib · Pfizer
- Xeljanz · Pfizer
Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs. - Xeljanz · Pfizer
Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation. - TOFA
Clinical guidelines
- FDA label — 1L
Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Juvenile psoriatic arthritis patent landscape — cliff calendar, originator estates, attackable patents
- Juvenile psoriatic arthritis treatment landscape brief
- Juvenile psoriatic arthritis treatment updates RSS
Frequently asked questions about Juvenile psoriatic arthritis
What drugs treat Juvenile psoriatic arthritis?
Tracked treatments include Tasocitinib, Xeljanz, TOFA.
What is the treatment for Juvenile psoriatic arthritis?
Standard treatment for Juvenile psoriatic arthritis includes Tasocitinib, Xeljanz, TOFA. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Juvenile psoriatic arthritis?
FDA label publishes guidelines for Juvenile psoriatic arthritis. 1 guideline references tracked.
Related
- Treatment landscape: Juvenile psoriatic arthritis patent cliff · Juvenile psoriatic arthritis CI report
- Treatment: Tasocitinib · Pfizer
- Treatment: Xeljanz · Pfizer
- Treatment: Xeljanz · Pfizer
- Treatment: TOFA
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing